Plasma protein variations in hemophiliacs receiving factor replacement therapy.

Area of Science:

• Hematology
• Clinical Biochemistry

Background:

• Hemophilia management involves frequent transfusions, necessitating an understanding of their effects.
• Plasma protein alterations are crucial to monitor in patients with hemophilia.

Purpose of the Study:

• To investigate the impact of factor replacement therapy on plasma protein levels in hemophilia patients.
• To compare plasma protein profiles between hemophiliacs, carriers, and healthy controls.

Main Methods:

• Analysis of 12 plasma proteins in 52 hemophiliacs and 68 carrier females.
• Utilized various electrophoretic techniques for protein examination.
• Compared results with healthy controls.

Main Results:

• Severe hemophiliacs exhibited significantly elevated levels of alpha-2-macroglobulin (a2 M), immunoglobulin G (IgG), and albumin (p < 0.05).
• Specific elevated values in severe hemophiliacs: a2 M (4.78 ± 0.865 g/l), IgG (21.48 ± 3.38 g/l), Albumin (66.26 ± 11.92 g/l).
• Controls and carrier females showed only minor variations in these plasma proteins.

Conclusions:

• Factor replacement therapy demonstrably influences plasma protein levels in severe hemophilia.
• Distinct differences in plasma protein profiles exist among hemophiliacs, carriers, and controls.
• Monitoring plasma proteins is important in assessing the effects of hemophilia treatment.